News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

McKesson Specialty Pharmacy Solutions Announces New Role for Key Executive

CARY, NC — November 2, 2017 — McKesson Specialty Pharmacy Solutions is pleased to announce Paula Bickley as Vice President, Market Access. In this new role, Paula will be tasked with expanding payer contracts to provide broader access to treatment for specialty pharmacy patients. In doing so, Paula will focus heavily on identifying solutions to… Read More

CALQUENCE® (acalabrutinib) Approved for Previously-Treated Mantle Cell Lymphoma, Available for Order at Biologics, Inc.

CARY, N.C. (November 1, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be in the limited distribution network for CALQUENCE® (acalabrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. CALQUENCE is a highly selectiv… Read More

VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (October 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM (abemaciclib), Eli Lilly’s first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration (FDA) on September 28,… Read More

BESPONSA® (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, available for order at Biologics, Inc.

CARY, N.C. (August 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA® (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Approved by t… Read More

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

CARY, N.C. (July 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment… Read More

Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy

Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes CARY, N.C. (June 27, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation from URAC, the healthcare industry’s leading certification and accreditation organization that evaluates quality standards. The independent non-profit organization promotes quality by ensuring… Read More

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

CARY, N.C. (May 24, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, secured more than $44 million in co-pay assistance in 2016 for commercial patients in need of oral chemotherapy drugs, easing the financial burden for these patients battling cancer. The Biologics’ Patient Access Services team also referred more than 38,000 unique patients to… Read More

IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (May 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be a specialty pharmacy provider in the limited distribution network for IMFINZITM (durvalumab). In addition to being available via specialty distribution, IMFINZI can also be dispensed by Biologics as a specialty pharmacy option. Approved… Read More

ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (May 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM (brigatinib). ALUNBRIG, an oral therapy for the treatment of patients wit… Read More

RYDAPT® (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, Available for Order at Biologics, Inc.

CARY, N.C. (May 3, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Novartis to be in the distribution network for RYDAPT® (midostaurin), a new oral treatment for adults with newly-diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. The AML treatment strategy has remained virtually… Read More